AbCellera Biologics Inc. (ABCL) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. AbCellera Biologics Inc. is a biotechnology company focused on antibody drug discovery and development. The company operates an integrated engine to discover antibodies for partners and develops its own internal pipeline. As of October 31, 2024, the company had approximately 295.4 million common shares outstanding.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $6.5 million | $6.6 million | $23.8 million | $28.8 million |
| Net Loss | $(51.1) million | $(28.6) million | $(128.6) million | $(99.2) million |
| Loss Per Share (Basic/Diluted) | $(0.17) | $(0.10) | $(0.44) | $(0.34) |
| Cash & Marketable Securities | $643.1 million (as of Sept 30, 2024) | |||
| Operating Cash Flow (YTD) | $(100.6) million | $(24.3) million |
Note: All figures in millions unless otherwise noted. Revenue consists primarily of research fees, licensing revenue, and milestone payments.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 18% year-over-year for the nine months ended September 30, 2024, driven primarily by a 20% decrease in research fees due to the timing and progress of R&D efforts.
- Significant Impairment Charges: The company recorded full impairment charges totaling $64.0 million in the first nine months of 2024. This includes $32.0 million related to In-Process Research and Development (IPR&D) from the Trianni acquisition (Q3 2024) and $32.0 million from the TetraGenetics acquisition (Q2 2024). These charges were due to internal program prioritization and discontinuance of specific development programs.
- Increased Operating Expenses: Total operating expenses increased significantly year-over-year (33% for Q3, 33% for YTD) largely due to the aforementioned impairment charges. Excluding impairments, R&D expenses decreased slightly YTD due to one-time investments in 2023, while G&A expenses increased due to higher legal and software costs.
- Other Income: Other income increased substantially YTD due to a $32.4 million non-cash fair value gain on contingent consideration (TetraGenetics) and a $16.5 million gain on the disposal of a non-marketable security.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes available liquidity (cash, marketable securities, and government contributions) is sufficient to meet working capital and capital expenditure needs for at least the next 36 months. No additional external funding is anticipated in this period.
- Government Contributions: The company continues to receive significant non-dilutive funding from the Government of Canada and British Columbia to build manufacturing capabilities and advance clinical trials. As of September 30, 2024, deferred government contributions totaled approximately $142.0 million (long-term) and $7.9 million (current).
- Key Risks:
- Profitability: The company has incurred losses since inception and may not achieve profitability. Future results depend heavily on partners successfully developing and commercializing antibodies.
- Revenue Volatility: Revenue is subject to significant fluctuation based on partner milestones and the timing of research programs. Royalty revenue from the Lilly partnership (COVID-19 antibodies) has ceased following the withdrawal of Emergency Use Authorization.
- Intellectual Property Litigation: Ongoing patent infringement litigation against Bruker Cellular Analysis (trial scheduled for January 2026) and civil litigation involving the Estate of John Schrader pose potential risks to operations and financial condition.
- Development Uncertainty: There is no guarantee that internal or partner programs will receive regulatory approval or become viable commercial products.
Investor Verification Checklist
- Verify the status and potential financial impact of the ongoing patent litigation with Bruker Cellular Analysis and the civil suit involving the Schrader Estate.
- Confirm the timeline and milestones for the Government of Canada and British Columbia contributions, specifically regarding repayment conditions and revenue thresholds.
- Monitor the progress of partner-initiated programs (currently 95 started, 14 molecules in clinic) to assess future milestone and royalty revenue potential.
- Review the company's capital allocation strategy regarding the construction of the GMP facility and headquarters to ensure alignment with the 36-month liquidity runway.
- Assess the impact of the IPR&D impairments on the remaining value of the Trianni and TetraGenetics acquisitions and future R&D prioritization.